| naltrexone versus placebo or no pharmacological treatments for opioid dependence |
|
Patient or population: patients with opioid dependence
Settings:
Intervention: naltrexone versus placebo or no pharmacological treatments |
| Outcomes |
Illustrative comparative risks* (95% CI) |
Relative effect
(95% CI) |
No of Participants
(studies) |
Quality of the evidence
(GRADE) |
Comments |
| Assumed risk |
Corresponding risk |
| Control |
naltrexone versus placebo or no pharmacological treatments |
| retention and abstinence, all patients |
Study population |
RR 1.43
(0.72 to 2.82) |
393
(6 studies) |
|
|
| 168 per 1000 |
240 per 1000
(121 to 474) |
| Medium risk population |
| 133 per 1000 |
190 per 1000
(96 to 375) |
| abstinence at follow up |
Study population |
RR 1.28
(0.8 to 2.05) |
116
(3 studies) |
|
|
| 340 per 1000 |
435 per 1000
(272 to 697) |
| Medium risk population |
| 364 per 1000 |
466 per 1000
(291 to 746) |
| side effects |
Study population |
RR 1.29
(0.54 to 3.11) |
159
(4 studies) |
|
|
| 270 per 1000 |
348 per 1000
(146 to 840) |
| Medium risk population |
| 360 per 1000 |
464 per 1000
(194 to 1000) |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; |
| GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate. |
